NYSE:NVRO

Nevro News Headlines

$148.87
-3.27 (-2.15 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$147.05
Now: $148.87
$152.72
50-Day Range
$132.81
MA: $147.76
$169.75
52-Week Range
$104.24
Now: $148.87
$188.14
Volume274,651 shs
Average Volume436,036 shs
Market Capitalization$5.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.02

Headlines

Nevro (NYSE NVRO) News Headlines Today

SourceHeadline
NVRO Crosses Above Key Moving Average Level - NasdaqNVRO Crosses Above Key Moving Average Level - Nasdaq
nasdaq.com - April 15 at 1:33 PM
Is NVRO Stock A Buy or Sell? - Yahoo FinanceIs NVRO Stock A Buy or Sell? - Yahoo Finance
finance.yahoo.com - April 13 at 3:57 PM
Is NVRO Stock A Buy or Sell?Is NVRO Stock A Buy or Sell?
finance.yahoo.com - April 13 at 3:57 PM
Nevro to Present at BofA Securities 2021 Virtual Health Care Conference - Yahoo FinanceNevro to Present at BofA Securities 2021 Virtual Health Care Conference - Yahoo Finance
finance.yahoo.com - April 13 at 10:56 AM
Nevro to Present at BofA Securities 2021 Virtual Health Care ConferenceNevro to Present at BofA Securities 2021 Virtual Health Care Conference
finance.yahoo.com - April 13 at 10:56 AM
Nevro to Report First Quarter 2021 Financial ResultsNevro to Report First Quarter 2021 Financial Results
finance.yahoo.com - April 7 at 9:43 AM
Nevro: Harvesting An Epic Growth Opportunity - Seeking AlphaNevro: Harvesting An Epic Growth Opportunity - Seeking Alpha
seekingalpha.com - April 6 at 8:09 AM
Nevro Announces Publication Of Landmark SENZA-PDN Clinical Trial Results In JAMA NeurologyNevro Announces Publication Of Landmark SENZA-PDN Clinical Trial Results In JAMA Neurology
finance.yahoo.com - April 5 at 2:21 PM
Zacks: Analysts Expect Nevro Corp. (NYSE:NVRO) Will Announce Quarterly Sales of $85.16 MillionZacks: Analysts Expect Nevro Corp. (NYSE:NVRO) Will Announce Quarterly Sales of $85.16 Million
americanbankingnews.com - April 4 at 2:42 AM
Nevro Corp. (NYSE:NVRO) Expected to Post Quarterly Sales of $85.16 MillionNevro Corp. (NYSE:NVRO) Expected to Post Quarterly Sales of $85.16 Million
americanbankingnews.com - April 4 at 2:42 AM
$85.16 Million in Sales Expected for Nevro Corp. (NYSE:NVRO) This Quarter$85.16 Million in Sales Expected for Nevro Corp. (NYSE:NVRO) This Quarter
americanbankingnews.com - April 4 at 2:42 AM
RSI Alert: Nevro (NVRO) Now OversoldRSI Alert: Nevro (NVRO) Now Oversold
nasdaq.com - March 26 at 8:31 PM
Why Is Nevro (NVRO) Down 16% Since Last Earnings Report? - Yahoo FinanceWhy Is Nevro (NVRO) Down 16% Since Last Earnings Report? - Yahoo Finance
finance.yahoo.com - March 26 at 3:30 PM
Why Is Nevro (NVRO) Down 16% Since Last Earnings Report?Why Is Nevro (NVRO) Down 16% Since Last Earnings Report?
finance.yahoo.com - March 26 at 3:30 PM
Nevro Corp. 2020 Q4 - Results - Earnings Call PresentationNevro Corp. 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 26 at 5:31 PM
At US$167, Is Nevro Corp. (NYSE:NVRO) Worth Looking At Closely?At US$167, Is Nevro Corp. (NYSE:NVRO) Worth Looking At Closely?
finance.yahoo.com - February 26 at 1:21 PM
Recap: Nevro Q4 EarningsRecap: Nevro Q4 Earnings
benzinga.com - February 25 at 12:17 PM
Nevro (NVRO) Q4 Loss Narrower Than Estimated, Revenues MissNevro (NVRO) Q4 Loss Narrower Than Estimated, Revenues Miss
nasdaq.com - February 25 at 12:17 PM
Nevro Corp (NVRO) CEO Keith Grossman on Q4 2020 Results - Earnings Call Transcript - Seeking AlphaNevro Corp (NVRO) CEO Keith Grossman on Q4 2020 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - February 25 at 7:16 AM
Nevro Corp (NVRO) Q4 2020 Earnings Call Transcript - Motley FoolNevro Corp (NVRO) Q4 2020 Earnings Call Transcript - Motley Fool
fool.com - February 25 at 7:16 AM
Recap: Nevro Q4 Earnings - Yahoo FinanceRecap: Nevro Q4 Earnings - Yahoo Finance
finance.yahoo.com - February 25 at 12:26 AM
Nevro Reports Fourth Quarter and Full Year 2020 Financial ResultsNevro Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - February 24 at 7:26 PM
Nevro Q4 2020 Earnings Preview - Seeking AlphaNevro Q4 2020 Earnings Preview - Seeking Alpha
seekingalpha.com - February 23 at 11:58 PM
Nevro (NVRO) May Report Negative Earnings: Know the Trend Ahead of Next Weeks Release - NasdaqNevro (NVRO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Nasdaq
nasdaq.com - February 17 at 2:34 PM
Nevro to Present at 10th Annual SVB Leerink Global Healthcare Conference - Yahoo FinanceNevro to Present at 10th Annual SVB Leerink Global Healthcare Conference - Yahoo Finance
finance.yahoo.com - February 4 at 12:44 AM
Nevro to Present at Citis 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual ConferenceNevro to Present at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference
finance.yahoo.com - February 1 at 9:27 AM
Nevro to Present at 10th Annual SVB Leerink Global Healthcare ConferenceNevro to Present at 10th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 1 at 9:27 AM
Nevro to Report Fourth Quarter and Full-Year 2020 Financial Results - Yahoo FinanceNevro to Report Fourth Quarter and Full-Year 2020 Financial Results - Yahoo Finance
finance.yahoo.com - January 27 at 5:36 PM
Nevro to Report Fourth Quarter and Full-Year 2020 Financial ResultsNevro to Report Fourth Quarter and Full-Year 2020 Financial Results
finance.yahoo.com - January 27 at 7:35 AM
Mainstay Medical Announces Key Strategic Hires to Drive Global Commercial Expansion - StreetInsider.comMainstay Medical Announces Key Strategic Hires to Drive Global Commercial Expansion - StreetInsider.com
streetinsider.com - January 25 at 12:39 PM
Nevro Corp.s (NYSE:NVRO) Path To ProfitabilityNevro Corp.'s (NYSE:NVRO) Path To Profitability
finance.yahoo.com - January 21 at 1:43 PM
Brain, Spine Stimulation Devices Are a Post-Pandemic Winner, Says Raymond James - BarronsBrain, Spine Stimulation Devices Are a Post-Pandemic Winner, Says Raymond James - Barron's
barrons.com - January 19 at 5:33 PM
NVRO Crosses Above Average Analyst Target - NasdaqNVRO Crosses Above Average Analyst Target - Nasdaq
nasdaq.com - January 14 at 5:37 PM
Nevro to Highlight New Clinical Evidence at the 2021 North American Neuromodulation Society (NANS) Virtual MeetingNevro to Highlight New Clinical Evidence at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting
finance.yahoo.com - January 14 at 12:35 PM
Nevro (NVRO) Posts Weak Preliminary Q4 and 2020 Revenues - Yahoo FinanceNevro (NVRO) Posts Weak Preliminary Q4 and 2020 Revenues - Yahoo Finance
finance.yahoo.com - January 12 at 1:20 PM
Nevro (NVRO) Posts Weak Preliminary Q4 and 2020 RevenuesNevro (NVRO) Posts Weak Preliminary Q4 and 2020 Revenues
finance.yahoo.com - January 12 at 1:20 PM
Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2020 Revenue - Yahoo FinanceNevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2020 Revenue - Yahoo Finance
finance.yahoo.com - January 11 at 10:17 PM
Nevro expects Q4 preliminary results to exceed guidance - Seeking AlphaNevro expects Q4 preliminary results to exceed guidance - Seeking Alpha
seekingalpha.com - January 11 at 5:12 PM
Nevro (NVRO) Announces Preliminary Q4 Revenue - StreetInsider.comNevro (NVRO) Announces Preliminary Q4 Revenue - StreetInsider.com
streetinsider.com - January 11 at 5:12 PM
Nevro Earns Relative Strength Rating Upgrade To 71 - Investors Business DailyNevro Earns Relative Strength Rating Upgrade To 71 - Investor's Business Daily
investors.com - January 11 at 5:12 PM
Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2020 RevenueNevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2020 Revenue
finance.yahoo.com - January 11 at 10:00 AM
Nevro falls after cautious mention from short seller - Seeking AlphaNevro falls after cautious mention from short seller - Seeking Alpha
seekingalpha.com - January 7 at 7:07 PM
These 5 Stocks Boast Impressive Interest Coverage Ratio - NasdaqThese 5 Stocks Boast Impressive Interest Coverage Ratio - Nasdaq
nasdaq.com - December 29 at 5:36 PM
Nevros (NVRO) FDA Submission to Treat Patients With PDN - Yahoo FinanceNevro's (NVRO) FDA Submission to Treat Patients With PDN - Yahoo Finance
finance.yahoo.com - December 29 at 5:36 PM
Nevros (NVRO) FDA Submission to Treat Patients With PDN - NasdaqNevro's (NVRO) FDA Submission to Treat Patients With PDN - Nasdaq
nasdaq.com - December 29 at 12:35 PM
Nevro Announces FDA Submission for HF10® Therapy in Patients with Painful Diabetic NeuropathyNevro Announces FDA Submission for HF10® Therapy in Patients with Painful Diabetic Neuropathy
finance.yahoo.com - December 28 at 7:59 PM
Nevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual ConferenceNevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual Conference
finance.yahoo.com - December 22 at 5:32 PM
Is NVRO A Good Stock To Buy According To Hedge Funds? - Yahoo FinanceIs NVRO A Good Stock To Buy According To Hedge Funds? - Yahoo Finance
finance.yahoo.com - December 22 at 12:31 PM
Is NVRO A Good Stock To Buy According To Hedge Funds?Is NVRO A Good Stock To Buy According To Hedge Funds?
finance.yahoo.com - December 22 at 12:31 PM
Nevro Corp.s (NYSE:NVRO) Intrinsic Value Is Potentially 49% Above Its Share PriceNevro Corp.'s (NYSE:NVRO) Intrinsic Value Is Potentially 49% Above Its Share Price
finance.yahoo.com - December 16 at 1:17 PM
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.